Ritocom

Lopinavir and Ritonavir, commonly known by their brand name Kaletra, represent a powerful combination therapy in the fight against HIV/AIDS. This dynamic duo operates as protease inhibitors, crucially disrupting the replication process of the virus within the body. By inhibiting the viral enzyme protease, they effectively impede the production of mature infectious viral particles, curbing the progression of the disease. Beyond their primary role in HIV treatment, Lopinavir and Ritonavir have also been explored for their potential in combating other viral infections, such as SARS-CoV-2, the virus responsible for COVID-19. Their synergistic action and established safety profile make them indispensable components of antiretroviral therapy regimens worldwide, offering hope and improved quality of life to millions of patients living with HIV.